Avita Medical Amends Credit Agreement with OrbiMed

An announcement from Avita Medical ( (RCEL) ) is now available.

On August 7, 2025, AVITA Medical announced a fifth amendment to its credit agreement with OrbiMed Advisors, adjusting revenue covenants and issuing common stock to the lenders. Despite facing challenges due to a temporary gap in Medicare payments, AVITA reported a 21% increase in commercial revenue for Q2 2025 compared to the previous year. The company anticipates recovery in RECELL demand in the second half of 2025 and has revised its full-year revenue guidance to reflect these developments.

The most recent analyst rating on (RCEL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.

Spark’s Take on RCEL Stock

According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.

Avita Medical’s stock score reflects a blend of strong revenue growth and technical momentum, offset by severe profitability challenges and high financial leverage. While future revenue projections and product expansions are promising, underlying financial weaknesses and valuation concerns present significant risks.

To see Spark’s full report on RCEL stock, click here.

More about Avita Medical

AVITA Medical, Inc. is a leading therapeutic acute wound care company that delivers transformative solutions. The company focuses on products like the RECELL System, which is designed to reduce hospital stays and improve recovery times for patients with trauma wounds.

Average Trading Volume: 317,008

Technical Sentiment Signal: Sell

Current Market Cap: $139.6M

For an in-depth examination of RCEL stock, go to TipRanks’ Overview page.